3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5%
HONG KONG, March 26, 2018 /PRNewswire/ -- Leading Chinese biotechnology company 3SBio(01530.HK) today released its 2017 annual results, showing that the company has been dramatically growing with important progress made in all businesses. Looking to the future, the company intends to reinforce it...
China FDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Patients with Type-2 Diabetes
SHANGHAI, Jan. 4, 2018 /PRNewswire/ -- 3Sbio Inc. (01530.HK) announced today thatChina's first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon® (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), ...
3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure
SHENYANG China, Sept. 3, 2017 /PRNewswire/ -- 3SBio Inc. (01530.HK, the "Group"), a leading Chinese biopharmaceutical company, is pleased to announce today that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture (the "JV") shall be established. The Group...
3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer
SHENYANG, China, Jan. 9, 2017 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatZhenping Zhu, MD, PhD, has joined 3SBio as its new President of Research & Development and Chief Scientific Officer. "We are pleased to ...
